Healthcare / Diagnostics & ResearchASX
$0.08
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-6.0M · quality 66.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$29M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-116.4%
↓Gross Margin
100.0%
↑Debt/Equity
0.38
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-31998.7%
FCF / Net income
0.96x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $21637.0 · net income $-7.2M · FCF $-6.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $21637.00 | $21637.00 | — | — | — |
| Net Income | $-7.2M | $-7.2M | $-6.4M | $-5.1M | $-3.4M |
| EBITDA | $-6.2M | $-6.2M | $-5.8M | $-7.8M | $-4.1M |
| EPS | -0.02 | -0.02 | -0.03 | -0.02 | -0.02 |
| Gross Margin | 100.0% | 100.0% | — | — | — |
| Operating Margin | -46043.0% | -46043.0% | — | — | — |
| Net Margin | -33466.0% | -33466.0% | — | — | — |
| Balance Sheet | |||||
| Debt/Equity | 0.38 | 0.38 | 0.18 | 0.20 | — |
| Current Ratio | 3.67 | 3.67 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-6.9M | $-6.9M | $-5.7M | $-6.0M | $-7.2M |
| Returns | |||||
| ROE | -116.4% | -116.4% | -74.5% | -97.1% | -35.1% |
| Valuation | |||||
| P/B | 4.62 | 4.62 | 4.01 | 3.28 | 1.70 |
| Growth & Yield | |||||
| EPS Growth | 22.7% | 22.7% | -8.3% | -44.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+6.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.03 → -0.02
Residual
+6.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.